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Abstract: The present investigation has been conducted on one hundred tissue fragments of breast
cancer, collected and immediately cryopreserved following the surgical resection. The specimens
were selected from patients with invasive ductal carcinoma of the breast, the most frequent and
potentially aggressive type of mammary cancer, with the objective to increase the knowledge of
breast cancer molecular markers potentially useful for clinical applications. The proteomic screening;
by 2D-IPG and mass spectrometry; allowed us to identify two main classes of protein clusters: proteins
expressed ubiquitously at high levels in all patients; and proteins expressed sporadically among
the same patients. Within the group of ubiquitous proteins, glycolytic enzymes and proteins with
anti-apoptotic activity were predominant. Among the sporadic ones, proteins involved in cell motility,
molecular chaperones and proteins involved in the detoxification appeared prevalent. The data of the
present study indicates that the primary tumor growth is reasonably supported by concurrent events:
the inhibition of apoptosis and stimulation of cellular proliferation, and the increased expression of
glycolytic enzymes with multiple functions. The second phase of the evolution of the tumor can be
prematurely scheduled by the occasional presence of proteins involved in cell motility and in the
defenses of the oxidative stress. We suggest that this approach on large-scale 2D-IPG proteomics
of breast cancer is currently a valid tool that offers the opportunity to evaluate on the same assay
the presence and recurrence of individual proteins, their isoforms and short forms, to be proposed
as prognostic indicators and susceptibility to metastasis in patients operated on for invasive ductal
carcinoma of the breast.
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1. Introduction
Breast cancer is still at the top of the statistics for the incidence among women worldwide but,
fortunately, the percentage of survival has significantly increased in all the western countries [1].
A recent retrospective study has reported that the five-year relative survival for the localized breast
cancer is 99%, while it drops to 84% when the cancer cells have spread to local lymph nodes, and to
26% when the cancer cells have invaded distant anatomic region and form metastasis [2,3]. These
results demonstrate that the primary prevention and early surgical removal save the lives of nearly all
women with breast cancer in the early stages.
The challenge now is to predict in time the propensity of the primary tumor to form metastases
and to be able to tackle or block them in time.
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Unfortunately, at present, there are not sufficient and accurate prognostic markers that can predict
the metastatic ability of tumor cells at the time of surgical resection, although many researchers are
seriously engaged in this challenge [4,5].
A major complication is that breast cancer is not a single disease: indeed clinical and pathological
evidence suggests the existence of several groups and subgroups of breast cancer, within the two major
histological types of ductal and lobular origin, each of them often displaying different biological and
clinical histories. In the majority of cases patients belonging to distinct subtypes respond differently to
the treatments and have dissimilar long-term survival rates [6].
Despite the histopathological differences among mammary tumors, there are similarities on
the conversion of a localized primary breast tumor to the invasive form, a process known as tumor
progression. A basic step involved in the tumor progression is the stepwise disruption of cell-cell
and cell-matrix contacts, followed by the loss of the polarized morphology, typical of the stationary
epithelial phenotype. Concurrently with the cell detachment from the tissue boundaries, the neoplastic
cells pass through the basal lamina and acquire a mesenchymal motile phenotype, while the cell-surface
becomes unstable displaying a ruffled appearance, with a tendency to release vesicles of a different
nature [7,8]. This phenomenon known as the epithelial/mesenchymal transition (EMT) is supported
by a set of genes inducing neoplastic cells to gain migratory and invasive properties towards the
surrounding and distant tissues [9,10].
The present work is a retrospective study of 100 surgical fragments obtained and cryopreserved
over the past years from patients operated on for invasive ductal carcinoma, which is the most frequent
and aggressive form of breast cancer.
The objective of this work was the identification of potential tumor markers for breast cancer by
applying the proteomic technique based on two-dimensional separation of the proteins followed by
their identification by mass spectrometry. This procedure permits to obtain simultaneous information
on the same assay, related to the occurrence of hundreds of proteins, their pI and MW coordinates, their
isoforms and short forms potentially useful as prognostic or predictive biomarkers. To our knowledge,
other important large-scale proteomic approaches are mainly bases on collective technical separation,
performed by multicenter investigation teams [11,12].
2. Materials and Methods
2.1. Clinical Specimens
Tissue aliquots of invasive ductal carcinoma of the breast (IDC) were obtained and
immediately cryopreserved, following surgical interventions during the years 2003–2007 at the
“La Maddalena” Hospital of Palermo, and intended for elimination after the completion of the
histopathological examination.
Research was carried out in compliance with the Helsinki Declaration with the patients’ written
consent. The patients of this study did not receive any therapeutic treatment before to surgery.
2.2. Sample Preparations
Aliquots of the frozen tissues (ranging from 0.5 to 1.00 g) were washed several times with PBS
and homogenized by a Polytron device in an ice bath. The homogenizing medium was: RIPA buffer
(50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA), containing a
mixture of protease and phosphatase inhibitors (0.01% aprotinin, 10 mM sodium pyrophosphate, 2 mM
sodium orthovanadate, 1 mM PMSF) [13]. The extraction was conducted overnight at 4 ◦C. The cellular
lysate was centrifuged to remove debris, and the supernatant was dialyzed against ultrapure distilled
water, lyophilized and stored at −80 ◦C.
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2.3. Two-Dimensional Gel Electrophoresis
The protein extracts were dissolved in a buffer composed by 4% CHAPS (3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate) (Sigma-Aldrich, St. Louis, MO, USA), 40 mM Trizma base
(Sigma-Aldrich, USA), 65 mM DTE (1,4-Dithioerythritol) (Sigma-Aldrich, USA) and a trace of
bromophenol blue in 8 M urea. Protein concentration was determined by the Bradford assay [14].
Protein samples (45 µg for the analytical gels, or 1.5 mg for preparative gels) were rehydrated in a
solution containing 8 M urea, 2% CHAPS, 10 mM DTE and 0.5% carrier ampholytes (Resolyte 3.5–10;
Amersham, Little Chalfont, UK), and applied to the strips for isoelectrofocusing (IEF) (18 cm long,
pH range 3.0–10, Bio-Rad, Hercules, CA, USA). After the IEF the strips were incubated in a solution
composed by 50 mM Tris-HCl pH 6.8, 6 M urea, 0.5% SDS, 30% Glycerol, 130 mM DTE and 135 mM
Iodoacetamide (Sigma-Aldrich).
The focused proteins were then separated on 9–16% linear gradient polyacrylamide gels
(SDS-PAGE) with a constant current of 20 mA/gel at 10 ◦C. The protein spots were revealed by
ammoniacal silver staining [15].
Silver-stained gels were analyzed with ImageMaster 2D Platinum software, Version 5.0
(Amersham, Little Chalfont, UK) with the support of the ExPaSy molecular biology server.
2.4. Protein Identification
The protein identity was searched by peptide mass fingerprinting using the Voyager DE-PRO
(AbSciex, Framingham, MA, USA) MALDI-TOF mass spectrometer as described [16]. In-gel digestion
of the protein spots was performed with sequencing-grade trypsin (Promega, Madison, WI, USA),
and the peptides were re-dissolved in 0.1% trifluoroacetic acid (TFA) and spotted in HCCA
(R-cyano-4-hydroxycinnamic acid) matrix (Sigma-Aldrich). The mass spectra were recorded in the
500–5000 Da range, using a minimum of 150 shots of laser per spectrum. Internal calibration was
performed using trypsin autolysis fragments at m/z 842.5100, 1045.5642, and 2211.1046 Da. Peptide
mass fingerprinting was compared to the theoretical masses from the Swiss-Prot databases using
the Mascot algorithms (http://www.matrixscience.com/). Search parameters were: 50 ppm of mass
tolerance, carbamidomethylation of cysteine residues, oxidation of methionine residues and one missed
enzymatic cleavage for trypsin. A minimum of four peptide mass hits was required for a match.
For the qualitative/comparative analysis the proteomic maps were matched by the algorithms of
the software Melanie utilizing immunologically validated anchors in the reference map (Figure 1).
For the comparative-quantitative analysis of the protein expression, the ratio between the average
intensities of individual protein spots in tumor over the non-tumoral tissues was calculated. Protein
classification was performed according to the major databases [17,18]. The proteins discussed in the
text are indicated with full name, abbreviated name and gene name (in brackets), according to the
ExPaSy molecular biology server.
2.5. Western Blot
For protein immune detection, the 2D-gels were electrotransferred onto nitrocellulose membrane
(HyBond ECL, Amersham) and stained with Ponceau S (Sigma Aldrich) as previously described [19].
The membranes were then probed with the following monoclonal antibodies (mAb): anti-actin (clone
JLA20) mouse mAb (1:1000; Merck KGaA); anti-GADPH (clone 0411) mouse mAb (1:1000; Santa
Cruz Biotechnology, Dallas, TX, USA, SCBT); anti-enolase (clone A5) mouse mAb (1:1000; Santa
Cruz Biotechnology, SCBT); anti-LGALS1 (clone 1E8-1B2) mouse mAb (1:1000; Novus Biologicals,
Littleton, CO, USA); anti-nm23-H1 (clone 37.6) mouse mAb (1:1000; Santa Cruz Biotechnology, SCBT);
and anti-psoriasin (clone 47C1068) mouse mAb (1:1000; Santa Cruz Biotechnology, SCBT. Following
incubation with goat anti-mouse IgG-HRP (1:5000, Santa Cruz Biotechnology, SCBT), the reaction was
revealed by the ECL detection system, using high performance films (Hyperfilm ECL, Amersham).
Proteomes 2017, 5, 15 4 of 31
Proteomes 2017, 5, 15 4 of 31 
 
 
Figure 1. A representative gel image of a breast cancer tissue. The graphic white boxes highlight the 
protein spots used as “anchors” for the gel alignment by the algorithms of the Image Master 
software. The side panels show the 2D-Western blot validations of the selected spots with the proper 
antibodies (anti-actin, anti-GADPH, anti-enolase, anti-LGALS1, anti-nm23-H1 and anti-psoriasin).  
3. Results 
Firstly, we wanted to compare the proteomic expression between the tumor tissues of breast 
cancer with healthy counterparts of the same patient.  
This analysis was previously conducted on a group of 13 patients with infiltrating ductal 
carcinoma (IDC) of the breast [20]. In Figure 2A,B, a prototype of twin maps, tumoral and 
non-tumoral updated to an increased number of spots (453 spots corresponding to 271 genes) is 
shown. For the qualitative/comparative analysis the maps were matched by the algorithms of the 
ImageMaster 2D Platinum software, utilizing immunologically validated anchors in the reference 
map, as shown in Figure 1. The quantification of the matching profiles was performed after 
normalization of the spot intensity values to the actin levels, as cellularity index [21] to correct for the 
different content of extracellular proteins in the tissue fragments. 
The graph in Figure 3 shows the layout of the two comparative densitometric profiles, where 
the differential pattern between tumoral and non-tumoral tissues is evident. Applying a cutoff value 
of 2 between the tumoral and non-tumoral tissues, more than 50% of the detected proteins showed 
higher expression levels in the tumors, while the remaining appeared unchanged and only a 
minority displayed a lower expression. Among the over-expressed proteins were: some glycolytic 
enzymes, different isoforms of S100 proteins, several proteins of the cell motility, and some proteins 
with anti-apoptotic activity.  
Supported by these results, we extended the investigation to an increasing number of breast 
cancer cases, focusing the research on the invasive ductal carcinoma (IDC) which is one of the most 
frequent and aggressive form of breast cancer. Here we report a retrospective proteomic analysis 
performed on 100 surgical fragments of patients operated on during the time lapse of the years 
2003–2007.  
These analyzes allowed us to verify the heterogeneous proteomic expression among patients. In 
particular, some proteins proved to be expressed in all of the tested cases (albeit at differential 
intensity) while other proteins showed an occasional or sporadic presence among the patients [22]. 
We considered ubiquitous proteins those present in at least 90% of patients and sporadic the 
remainder, meaning absent the spots missing perceptible signal in the matched maps. 
Figure 1. A representative gel image of a breast cancer tissue. The graphic white boxes highlight the
protein spots used as “anchors” for the gel alignment by the algorithms of the Image Master software.
The side panels show the 2D-Western blot validations of the selected spots with the proper antibodies
(anti-actin, anti-GADPH, anti-enolase, anti-LGALS1, anti-nm23-H1 and anti-psoriasin).
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Table S1 (supplementary data) shows the catalogue of proteins collectively identified by 2D-IPG
followed by mass spectrometry of the individual spots. Different isoforms of the same protein were
labelled by alphabetical letters starting with a.
The differential patterns of the proteins expressed in the 100 maps is represented in the diagrams
reported in the supplementary Figure S1, where in the x-axis are the patients ordered with progressive
numbers and in the y the protein names. The white boxes represent the presence and the grey ones the
absence of individual protein spots. As a whole, the ubiquitous proteins were 63% of identified total
proteins while the sporadic ones were 37% of the total identified spots.
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Figure 2. Representative proteomic maps of a breast cancer tissue (A) and its non-tumoral adjacent 
tissue (B). Protein spots of known identity are labelled with the access number of the 
Swiss-Prot/TrEMBL database. Different isoforms of the same protein are jointly labelled. 
Figure 2. Representative proteomic maps of a breast cancer tissue (A) and its non-tumoral
adjacent tissue (B). Protein spots of known identity are labelled with the access number of the
Swiss-Prot/TrEMBL database. Different isoforms of the same protein are jointly labelled.
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Figure 3. Global densitometric profiles of the proteomic maps shown in Figure 2, illustrating the 
relative differences in the actin-normalized intensity values of protein spots from tumoral (BCT, grey 
line) and non-tumoral adjacent tissue (BNT, black line). 
3.1. Ubiquitous Proteins 
Among the ubiquitously over-expressed proteins, worthy of note was the detection of several 
isoforms of key glycolytic enzymes, several proteins with anti-apoptotic activity, members of the 
S100 protein family and several members of the proteasome complex. Concerning the S100 proteins, 
eight family members were ubiquitously expressed among the patients and seven were sporadic.  
Moreover, a generalized expression of a typical mesenchymal marker, the cytoskeletal 
vimentin, was found in contraposition to the statistical decrease of cytokeratins in the patients.  
The diagram in Figure 4A shows the occurrence of glycolytic enzymes, including isoforms (29 
members); the diagram 4B represents the occurrence of a “transverse” class of heterogeneous 
proteins (39 members), each performing peculiar functions, which share the activity of apoptosis 
regulation, performed through diverse pathways; the diagram 4C shows the occurrence of the 
ubiquitous S100 proteins (8 members), and the diagram 4D represents proteins of the proteasome 
complex (17 members).  
To assess the levels of the mean expression of these groups of ubiquitous proteins, the average 
values of the individual proteins and their isoforms were plotted against the media of 10 selected 
healthy tissues as a reference. The quantification of the expression levels of the individual protein 
spots was evaluated through the intensity values normalized to the actin content in each map [21] 
and reported in Figure 5A–D. As can be observed in the diagrams, some of the glycolytic enzymes 
did not show differential expression levels between normal and breast cancer tissues, namely the 
ENOA forms, the two isoforms of PGAM1 and the 5 isoforms of TPIS. Conversely, the other detected 
enzymes of the glycolytic pathway displayed a significant increase with respect to the 
corresponding normal ones, namely: the two isoforms of ALDOA, the 5 isoforms of G3P, the 4 
isoforms of KPYM and the 3 forms of the PGK1. Moreover, the high expression of the ENOG, 
usually absent in the non-tumoral tissues, was observed. 
Concerning the group of regulators of apoptosis, all members showed significant increase in the 
tumoral tissues, with a maximum peak for cofilin (about 14 folds). 
In the group of S100 proteins, the only member that did not show any variation between normal 
tissues and the tumors, was the S100A6 with its two isoforms; all the other members displayed a 
significant increase in cancer. 
Finally, the group of proteasome complex subunits (17 members) showed a significant increase 
with respect to the normal counterpart.  
The remaining proteins, not included in the above reported classes, were recognized by the 
databases as belonging to the following functional classes: protein folding, tricarboxylic acids cycle, 
protein biosynthesis and exosomes. 
Figure 3. Global densitometric profiles of the proteomic aps shown in Figure 2, illustrating the relative
differences in the actin-normalized intensity values of protein spots from tumoral (BCT, grey line) and
non-tumoral adjacent tissue (BNT, black line).
. . i i t i
t i i , t t ti f s r l
i f r s of key glycolytic enzymes, ev ral proteins with anti-apopt tic activity, members of the S100
protein family and several members of the prot asome c plex. Concerning the S100 proteins, eight
family members were ubiquitously expressed among the pa ients and seven were spo adic.
r er, a gen ralized expression f a typical mesenchymal marker, the cytoskeletal vim ntin,
was fou d in contrapositi to the statistical decrease of cytokeratins in the patie ts.
i Figure 4A shows the occurrence of glycolytic enzymes, including isoforms
(29 embers); the di gram 4B repr sents the occurrence of a “transverse” l hetero e
r t i ( e rs), erf r i li f t ti it f a t i
l i t
i t i r r t i f t e proteas
l ( rs).
o assess the levels of the ean expressio of these gro s of ubiq it s r tei , t r
l f t i i i l r t i t i is f l tt i t i f s l t
l ti refere ce. fi l t i i i l r t i
ts as evaluated through the intensity values normalized to the actin content i each map [21] and
repo ted in Figure 5A–D. As can be observed in the diagrams, some of the glycol tic enzymes did
not sh w differential expression levels between normal and breast cancer tissues, namely the ENOA
forms, the two isoforms of PGAM1 and the 5 isoforms of TPIS. Conversely, th other detected enzym s
of the glyc lytic pathway d splayed a significant increase w th respect to the corresponding n rmal
ones, namely: the two isoforms of ALDOA, the 5 is forms of G3P, the 4 isoforms of KPYM and the
3 forms of the GK1. Moreover, the high expression of the ENOG, usually absent in the non-tumoral
ti sues, wa observed.
r i t f l t rs f t is, ll i ifi t i r se i t
t r l tiss s, it a axi eak for cofilin (about 14 folds).
I t f t i s, t l r t t i t i ti l
ti t t , t it it t is f r ; ll t t r i l
i ific t i crease in cancer.
i ll , the group of proteaso e co plex s b its ( e rs) i ifi t i
it respect to the nor al counterpart.
Proteomes 2017, 5, 15 7 of 31
The remaining proteins, not included in the above reported classes, were recognized by the
databases as belonging to the following functional classes: protein folding, tricarboxylic acids cycle,
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Figure 4. Diagrams illustrating the occurrence of the ubiquitous proteins (ordinate axis) among the 
100 studied patients (abscissa axis). Proteins are indicated according to the Swiss-Prot/TrEMBL 
database. Isoforms are reported with alphabetical letters. The white boxes indicate the presence of a 
given protein (or isoform) and the grey boxes its absence in the corresponding patient map. The 
ubiquitous proteins are sorted in the following classes: (A) Glycolysis; (B) Regulation of Apoptosis; 
(C) S100 Proteins with ubiquitous expression and (D) Proteasome complex.  
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Figure 5. Comparative expression of the normalized average intensity levels between the ubiquitous 
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The bars indicate the standard deviation. 
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belonging to the following functional classes: cell adhesion, nucleotide binding, mitochondrial 
proteins, intracellular transport and exosomes. 
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Figure 6. Qualitative data analysis illustrating the occurrence of the sporadic proteins (ordinate) 
among patients, indicated by 1 to 100 (abscissa), as reported in Figure 4. The sporadic proteins are 
sorted in the following classes: (A) Cytoskeleton Organization and Cell Motility; (B) Chaperones, 
Folding and Vesiculation; (C) S100 Proteins with sporadic expression and (D) Detoxification.  
Figure 6. Qualitative data analysis illustrating the occurrence of the sporadic proteins (ordinate) among
patients, indicated by 1 to 100 (abscissa), as reported in Figure 4. The sporadic proteins are sorted in
the following classes: (A) Cytoskeleton Organization and Cell Motility; (B) Chaperones, Folding and
Vesiculation; (C) S100 Proteins with sporadic expression and (D) Detoxification.
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vimentin isoforms. Namely the cytokeratins, all sporadically expressed, were: three isoforms of 
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tumors display a clear epithelium/mesenchyme transition.  
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point and molecular mass. The majority of these incomplete forms (63.4%) was ubiquitously expressed
on the analyzed breast cancer samples, whereas the remaining occurrence was sporadic.
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At present we have unequivocally identified 453 protein spots reported in a reference 
proteomic map referred to the 100 selected patients. To evaluate the occurrence and frequency of 
individual proteins and their isoforms, we have built an extensive Cartesian-style diagram where 
the patients (indicated by the increasing numbers) were reported in the axis of abscissas and the 
protein abbreviated names in the axis of ordinates.  
Proteins detected in at least 90% of the patients, and therefore designed as ubiquitous, 
represented 63% of the total, while the remaining 37% displayed a sporadic presence within the 
patients. 
4.1. Ubiquitous Proteins 
Among the ubiquitously overexpressed proteins, about 9% belongs to the category of glycolytic 
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4.1. Ubiquitous Proteins
Among the ubiquitously overexpressed proteins, about 9% belongs to the category of glycolytic
enzymes and their isoforms, 13.3% belongs to the transverse group of proteins with regulative activity
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on apoptosis, 2.8% to the S100 proteins, 5.6% to the Proteasome complex and the others are scattered
among the various classes of proteins with metabolic or structural functions.
4.1.1. The Overexpressed Glycolytic Enzymes
It is known since the times of Otto Warburg [23], who first described the phenomenon, that cancer
cells exhibit a transition from the aerobic metabolism to the anaerobic glycolysis. This event, formerly
interpreted as a consequence of a hypoxic environment within the tumor mass, appears plausible, but
not exclusive to justify the increased protein expression of several key enzymes of the glycolysis, also
under normoxic conditions “in vitro” [24], and in mammospheres [25]. Indeed, increased levels of
gene expression of several glycolytic enzymes have also been detected in several cancer types [26].
Our present results showed that in a statistical average of 100 cases of invasive ductal carcinoma
an increase of some key glycolytic enzymes occurred, namely: ALDOA, G3P KPYM, PGK1, and LDHA,
while no relevant increase was observed for other glycolytic enzymes (i.e., ENOA, PGAM1, TPIS).
Several investigations during the past years have, however, revealed numerous other
non-glycolytic functions carried out by different enzymes among the canonical 10 of the
glycolytic pathway.
Fructose-bisphosphate aldolase A, ALDOA (ALDOA). Literature data shows that ALDOA is
over-expressed in many types of cancers, including hepatocellular carcinoma [27], squamous cell
lung cancer [28,29], osteosarcoma [30], colorectal cancer [31]. The recognized non-glycolytic functions
of ALDOA include: participation to signal transduction [32], vesicle trafficking [33], cell motility [34]
and epithelial-to-mesenchymal transition [35]. In addition, ALDOA may be phosphorylated by Akt
or Erk 2 kinases and then it can move into the nucleus, where it may be involved in the regulation of
transcription of genes implied in cell cycle progression [36] and the DNA protection [37].
The ubiquitous overexpression of ALDOA in all of the 100 patients studied supports the relevance
of this increased expression in driving or sustaining elevated proliferation rhythm in cancer.
Glyceraldehyde-3-phosphate dehydrogenase, G3P (GAPDH). The GAPDH gene has been classically
used as a housekeeping gene, but in more recent years it has been shown to be over-expressed in
many tumors including breast cancer and to be correlated with a poor prognosis [38] and an increased
drug resistance [39]. In particular, it has been reported that GAPDH overexpression is associated
with cell proliferation via its effects following direct or indirect (through binding with the protein
SET) interactions with cyclin B-cdk1 [40]. These effects concern mainly an acceleration of cell cycle
progression and an increased number of mitosis. Moreover, it has been demonstrated that when
the G3P binds to its substrate, the glyceraldehyde-3-phosphate, the small GTPase Rheb is released
and it works as a positive regulator of mTORC1, an essential pathway regulating many cellular
responses to growth factors [41]. These additional functions of the enzyme depend in particular
on the dislocation from its native cytoplasmic location. Indeed, it can migrate to the nucleus or to
the mitochondria where it may perform additional functions beyond the glycolytic pathway [42,43],
this also by post-translational modifications induced, for example, by exposure to various stresses [44].
Moreover, the deregulation of glycolytic enzymes in cancer may cause cascading consequences
with adverse outcomes for patients. Among the most remarkable targets are membrane trafficking,
microtubule assembling, phosphotransferase activity, binding of nucleic acids [45]. For these reasons,
G3P is presently included in the possible therapeutic targets [46].
The capability of G3P to promote cell proliferation, together with its elevated and ubiquitous
expression in our breast cancer tissues, strongly supports an oncogenic role for this protein.
Pyruvate kinase, KPYM (PKM). It has been demonstrated that this enzymes, besides its role in the
glycolytic pathway, interacts and cooperates with Oct-4, a gene which encodes a transcription factor
performing a significant role in sustaining the pluripotent state of embryonic stem cells and preventing
the expression of differentiation genes [47].
It is worth noting that in our 100 cases of tumors, two of the four isoforms were
ubiquitously over-expressed.
Proteomes 2017, 5, 15 13 of 31
L-lactate dehydrogenase A chain, LDHA (LDHA). It has been reported in the literature that this
enzyme, involved in step 1 of the glycolytic subpathway promotes cancer cell invasion, anoikis
resistance, and tumor metastasis, via HER2 and Src pathways [48,49]. It has also been shown that an
experimentally increased expression of 14-3-3ζ in human mammary epithelial cells up-regulates
LDHA expression, elevates glycolytic activity, and promotes early transformation through the
MEK-ERK-CREB axis [50]. Present data supports these mentioned literature records.
Phosphoglycerate kinase 1, PGK1 (PGK1). Many types of cancers, including those of the breast [51],
the colon [52], the liver [53] and others, have been shown to exhibit an increased expression of
PGK1. Indeed, it has been demonstrated that, in addition to its role as a glycolytic enzyme, PGK1
may act as a promoter of cancer progression and induce chemoresistance for some drugs [51,52].
Moreover, this protein may be secreted by tumor cells, in spite of the absence of the appropriate
signal sequence, and participate in the “angiogenic switch” by reducing disulfide bonds in the serine
protease, plasmin [54,55]. The ubiquitous overexpression of PGK1 in our 100 tumor samples supports
the hypothesis of the important role played by this protein in tumorigenesis.
Finally, it is worth mentioning that the other key enzyme of the glycolytic pathway, the ENOA,
is highly expressed both in normal and tumoral tissues. On the contrary, the ENOG, which is known to
be specific for nervous tissues, is almost absent in the non-tumoral tissues and ubiquitously expressed
at very high levels, in the tumor tissues. Its role in breast cancer has not yet been clarified [56].
4.1.2. Regulators of Apoptosis
Apoptosis is a genetically programmed process which brings cells to suicide following different
injuries. In normal conditions of tissue renewal and during development, there is a controlled balance
between cell division and cell death. This equilibrium is lost during carcinogenesis, where cell
proliferation prevails over cell death. There are two major apoptotic pathways, extrinsic and intrinsic,
involving some different proteins, the majority of them also performing several different cellular
roles [57]. Recently a paradox of function has been attributed to the apoptosis in cancer, postulating a
pro-tumoral function of the apoptotic process [58].
The group of proteins that we classified under the name of “regulators of apoptosis” is a
“transverse” group of proteins since they perform several distinct functions, but they share the
apoptosis regulation activity, documented in the gene ontology databases [59]. Some of these proteins
also perform important roles in the complex scenario of the progression of various cancers.
With the exclusion of COF1, which shows ambivalent roles, all the other members were classified
as anti-apoptotic proteins by the databases.
The proteins included in this group are indicated below.
The 14-3-3 multi-gene family. The multigenic protein family 14-3-3 includes several members
that can generate homo- or heterodimers [60]. In mammals seven genes (β, ε, η, γ, τ, ζ and σ) have
been identified so far, all of them acting as key regulators of several intracellular signaling pathways.
These include cell cycle regulation, apoptosis, control of metabolism and gene transcription [61], and
maintenance of epithelial cell polarity [62]. The mechanisms of action of the 14-3-3 proteins are varied
according to their specific functions in tissues: indeed they may activate or stabilize some proteins
and inactivate others; in many cases, they perform a role of scaffold molecules [63]. In our proteomic
maps, we have recognized 4 out of 7 members of the family (β, γ, ζ and σ), having different occurrence
in cancer tissues. Among these, the 14-3-3 γ and 14-3-3 σ were found ubiquitously expressed in all
patients, while the other isoforms have been found sporadically present among the patients.
Several studies in the field of oncology have demonstrated that the tumoral transformation is
associated with the onset of antiapoptotic mechanisms. In this respect, a major anti-apoptotic and
pro-proliferative role of the 14-3-3 proteins, within a complex network of protein-protein interactions
in cancer, has been highlighted [64–66].
The occurrence of the gamma form in 100% of our breast cancer cases and 98% of the sigma
form underlines the important role of these isoforms in raising the anti-apoptotic activity during the
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primary tumor growth, so confirming and strengthening the involvement of the 14-3-3 proteins in the
molecular processes critical for tumor progression.
The Annexins. Annexins consist of 13 members of Ca2+ and phospholipid binding family
of peripheral membrane proteins. Mostly, they can bind the phospholipid of the membranes in
a Ca2+ dependent manner and perform subsequent activities related to membrane trafficking,
signal transduction, and exocytosis [67]. In our proteomics study, we have found a ubiquitous and
over-expressed presence of ANX1A and of two isoforms of ANXA5 which are known to play an
anti-apoptotic role and are thought to be involved at different levels in the tumor development,
progression and invasivity [68–70]. Therefore both of them are regarded as potential tumor markers [71],
a hypothesys shared by this study.
Catalase, CATA (CAT). The catalase is an antioxidant enzyme which plays the first line of defense
against free radicals, removing hydrogen peroxide from cells. It is known to exert an anti-apoptotic
role in several tumors [72]. In our tissues, we detected two isoforms of CATA, one of which appeared
ubiquitously expressed, but with a modest average increase with respect to the normal tissues.
Cofilin, COF1 (CFL1). The COF1 is a protein mainly involved in the actin cytoskeleton organization
during the normal progress through mitosis and cytokinesis. It is also required for the maintenance of
cell morphology and the cell motility [73]. Concurrently, it is involved in the regulation of apoptosis.
However, in this context, it appears to have ambivalent roles, since in many cases it showed to play
pro-apoptotic activity and in others anti-apoptotic [74–76]. In our samples we have identified four
cofilin isoforms, one of these was ubiquitous, displaying a very higher expression level (14×) on the
non-tumoral tissues. New literature evidence associates the high expression levels of cofilin and its
dephosphorylated form, with poor prognosis in breast cancer patients [77].
The ubiquitous heat-shock proteins (HSPs). The heat-shock proteins, formerly discovered as proteins
of response to heat-stress injury, represent a large protein family mainly involved in protein folding and
playing significant roles in cellular proliferation, differentiation, and protection of cells from stress [78].
According to their molecular size the HSPs have been classified into six major families (HSP100, HSP90,
HSP70, HSP60, HSP40, and small heat shock proteins sHSPs). Some of them perform their functions in
both the cytosolic and the nuclear compartments (i.e., HSP90), others in the endoplasmic reticulum
(i.e., GRP94) or other subcellular compartments (i.e., the mitochondrial HSP70) [79].
HSPB1 (HSPB1) and CH60/HSP60 (HSPD1). It has been reported that the HSPs display elevated
expression levels in cancer, where they may perform anti-apoptotic activities both spontaneous and
generated by therapy [80]. In particular, the high expression of HSPB1 has been associated with poor
prognosis in several carcinomas and osteosarcomas [81], while CH60, with annexin-2, is considered a
potential biomarker for subtypes of lung carcinoma [82]. A result of the interest of our study, which
deserves further investigation, was the detection of seven isoforms of HSBP1, four ubiquitous and
three sporadic, and of four isoforms, three ubiquitous and one sporadic of the CH60. One of the
ubiquitous forms of CH60, that appeared the closest to the expected values for the primary gene
product, showed a high average increase (6 folds) with respect to the non-tumoral tissues.
78 kDa glucose-regulated protein, GRP78 (HSPA5). This protein, also known as Binding
immunoglobulin Protein (BiP), or Heat Shock 70 k, is a member of the heat shock protein
70 (HSP70) family. Its primary function is that of molecular chaperone within the lumen of the
endoplasmic reticulum, where it binds newly synthesized proteins as they are translocated into the ER.
Its anti-apoptotic role has also been reported [83]. In addition, it may regulate the TGF-β pathway,
through the molecular interaction with its ligand Crypto, an oncofetal GPI-anchored/secreted signaling
protein, which plays a key role as a stem cell regulator [84]. For these reasons, Cripto/GRP78 complex
represents a possible therapeutic strategy for the treatment of human cancer [85]. Interestingly,
this protein has been found ubiquitously present in all of our patients and sporadically in the
non-tumoral tissues.
Endoplasmin, ENPL/GRP-94 (HSP90B1). The endoplasmin, paralogue of the cytosolic heat shock
protein 90 (HSP90), is a molecular chaperone for the processing and transport of secreted proteins; it has
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been shown to be a ligand for multiple receptors including Toll-like receptors, Wnt and integrins [86].
More recent preclinical studies have also revealed that GRP94 expression is closely related to advanced
stage and poor survival of patients in a variety of cancers [87]. This protein was ubiquitously expressed
in our tissues where it showed a moderate increase versus the non-tumoral tissues.
Lactoylglutathione lyase LGUL (GLO1). This enzyme catalyzes the conversion of hemimercaptal,
formed from methylglyoxal and glutathione to S-lactoylglutathione. It is also involved in the regulation
of transcriptional activity of NF-kappa-B induced by TNF. Interestingly, it appears to be required for
normal osteoclastogenesis and therefore involved in the complex mechanism of bone metastasis [88].
In our tumor tissues, LGUL showed a moderate fold increase on the non-tumoral tissues.
Macrophage Migration Inhibitory Factor, MIF (MIF). This factor is involved in several biological
activities which ultimately may support cancer progression [89]. The expression of this protein
stimulates the production of cytokines, chemokines, and growth factors, as well as angiogenic factors,
that favor the tumor growth also potentiating its aggressiveness and metastatic spreading [90,91].
The overexpression of MIF has been demonstrated in breast cancer cells, in which, through the
interaction with HSP90 and CXCR-4, MIF induces resistance to the apoptosis and stimulates the
proliferation via AKT pathway [91]. In our tissues, we found two isoforms of MIF, one of which
ubiquitous and highly overexpressed (6×).
Nucleoside diphosphate kinase B, NDKB (NME2). The gene coding for this protein was the first
anti-metastatic gene to be discovered [92] and correlated with good prognosis in multiple tumor
types [93]. It plays a major role in the synthesis of nucleoside triphosphates other than ATP. Moreover,
it regulates negatively Rho activity by interacting with AKAP13/LBC, and may act as a transcriptional
activator of the MYC gene [94]. In our samples, the NDKB showed a significant fold increase (6.4×)
versus the non-tumoral tissue.
Nucleophosmin, NPM (NPM1). The NPM1 plays critical roles in many cellular processes,
including protein chaperoning, cell proliferation and apoptosis. In consideration of its multifunctional
potentiality NPM1 can play roles both as a proto-oncogene and as a tumor suppressor [95,96]. In our
tumor tissues, we observed its moderate increase on the non-tumoral tissues.
Parkinson disease protein 7, PARK7/DJ1 (PARK7). This protein plays a central function as deglycase
in several cytoplasmic pathways. It is also involved in protecting cells against oxidative stresses and
apoptosis, acting as oxidative stress sensor and redox-sensitive chaperone. It is mutated in several
neurodegenerative disorders, most notably Parkinson’s disease [97]. In the context of cancer, it has been
suggested that it promotes cell survival by enhancing AKT phosphorylation and thus the inhibition
of PTEN function [98,99]. It has been reported that in patients with lung, ovarian and oesophageal
cancers, high expression of PARK7 predicts a poor outcome [100]. Moreover, high expression of
PARK7 in breast cancer potentiates HER3 signaling and therefore may serve as a target for molecular
therapies [101]. In our tissue samples, we have identified four isoforms one of which was ubiquitous
and moderately over-expressed on the non-tumoral tissues.
Superoxide dismutase (Mn) mitochondrial, SODM (SOD2). The SODM is an enzyme which destroys
superoxide anion radicals normally produced as metabolic waste, toxic to biological systems. It has
been demonstrated that SOD2 exerts an anti-apoptotic effects attributed to its ability to generate
H2O2 [102]. This enzyme appeared ubiquitously increased in all of our tumoral tissues (3×).
Translationally-controlled tumor protein, TCTP (TPT1). The classical roles of this protein are
the calcium binding and microtubule stabilization. In addition, it has been found engaged
in the epithelial to mesenchymal transition and in the promotion of cell migration, invasion,
and metastasis [103,104]. In our tumoral tissues, we found a single form of it, increased of 3× with
respect to the non-tumoral tissues.
Thioredoxin, THIO (TXN). The thioredoxin is a small protein playing pivotal roles in redox
homeostasis and cell survival, and it is usually highly expressed in many cancers [105]. Indeed,
in response to reactive oxygen species (ROS) associated with the tumors, thioredoxin and DJ-1 are
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upregulated to limit or reverse cell damages [106,107]. In our samples, we found two close isoforms of
thioredoxin increased respectively of 3.7 and 2.5 folds in tumors.
Voltage-dependent anion-selective channel protein 2, VDAC2 (VDAC2). This protein is a member
of the VDAC family and shares structural homology with the other VDAC isoforms (VDAC1 and
VDAC3), which are involved in the regulation of metabolite diffusion across the mitochondrial outer
membrane. It has been stated that the overexpression of VDAC2 prevents BAK activation and inhibits
the mitochondrial apoptotic pathway [108]. The high increase (6.7×) of this anti-apoptotic protein in
all the patients studied is a further indication of the importance of the anti-apoptotic systems to ensure
the unchallenged growth of cancer cells.
No relevant differences in the average of expression levels between tumoral and non-tumoral
tissues were observed for the other components of the group: i.e., COR1A, DDAH2, GDIR1, GSTP1,
PRDX2, PRDX3, RL40.
4.1.3. Ubiquitous S100 Proteins
The S100 proteins are members of a multigenic family of calcium-binding proteins of the EF-hand
type, encoded by 21 genes in human [109]. Members of the S100 family are differentially distributed
in tissues [110] where they perform a great variety of functions. They may act intracellularly or may
be released into the microenvironment and exert extracellular regulatory effects [111]. Intracellular
functions include calcium homeostasis, regulation of phosphorylation, regulation of gene expression,
cytoskeleton dynamics and cell motility. Their extracellular activities are fulfilled in a cytokine-like
manner through the receptor for advanced glycation end products (RAGE) [112]. Some of the secreted S100
proteins may exert chemotactic [113] and antibacterial actions [114].
Their frequent altered expression has been correlated with various aspects of the tumor growth
and progression [115]. In our breast cancer tissues, we recognized 15 members, including isoforms,
corresponding to 10 genes, eight of them (corresponding to 5 genes) were ubiquitous.
S10A2 (S100A2). Among the ubiquitous S100 protein members, the S100A2 is the one showing a
higher index of fold increase (about 30 times) on the average of non-tumor tissues. This significant
increase agrees with the role attributed in the literature to this protein [115]. However, concerning its
role in the apoptosis, literature data shows an often contradictory role of S100A2 which in some cases
works as a tumor suppressor [116], and in others, as a tumor promoter [117].
S10A6 (S100A6). This protein was found expressed at high levels in both tumor and non-tumoral
tissues, confirming the key role and leadership attributed to this protein, as calcium sensor and
modulator, in sustaining many physiological processes, among which the reorganization of the actin
cytoskeleton and in cell motility [118].
S10AB (S100-A11). This is a calcium-binding and cadherin-binding protein also involved in
cell-cell adhesion. In our tissues we detected three isoforms of it, all of them expressed at high levels in
tumors and nearly absent in the normal tissues. Literature data reports that the increased expression
of S100A11 contributes to the growth of certain tumors, due its activity of negative regulation of cell
proliferation [119,120].
S10AD (S100A13). S10AD has been proposed to play roles in the invasiveness of lung cancer
cells [121] and angiogenesis of human melanoma [122]. In our tissues, we found two isoforms
of it, one of which ubiquitous, showing a moderate fold increase, and the second, more basic,
expressed sporadically.
S10AG (S100A16). This member of the S100 protein family has been reported to be involved
and overexpressed in several pathological affections, including cancer, but with different and often
contradictory roles [123–125]. In our tumor tissues, we found a single form of S10AG with a fairly high
increase (3×) versus the normal tissues.
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4.1.4. Proteasome Subunits
The high proliferation rate in cancer has destabilizing effects on many cytoplasmic proteins. There
are at least two systems to counteract these disadvantages: the system of degradation, of which the
ubiquitin-proteasome is the leader, and the chaperone system consisting of various stress-induced
proteins (HSPs). A proper capability to degrade the misfolded proteins is crucial for cell survival,
while the impairment of this function contributes to the aging and neurodegeneration. More recently,
a paradoxical function has been proposed for the proteasome system as being a promoter of cell
survival and tumor progression [126].
In our tissue maps, we detected the ubiquitous presence of 15 proteasomal subunits coded by
15 genes. The majority of them showed a higher average expression on the non-tumoral tissues,
with peaks for PRS6A (11×), PSME1 (18×), and PSA7 (26×).
4.2. Epithelium-Mesenchymal Transition (EMT) Markers
A result of considerable interest was the identification of the concurrent expression of key
elements of the epithelial-mesenchymal transition in the tumor samples: indeed eight protein spots
corresponding to vimentin and its fragments were ubiquitously present in all samples, while 14 CK
forms, isoforms and fragments, were highly sporadic among the tissues.
The phenomenon of epithelium-mesenchyme transition has been much studied in recent
years [9,10,127] and represents one of the key features in the transition from a stationary to a motile
cellular phenotype during tumor progression. To our knowledge, this is the first evidence of a collective
expression pattern at the proteomic level of the EMT pattern in breast cancer and may be of great
utility for more accurate and personalized histo-pathological diagnoses.
4.3. Sporadic Proteins
We classified as “sporadic” the proteins that occur in less than 90% of the patients studied. These
represent 37% of the spots identified in proteomic maps. They were divided into four main classes
with the support of the database DAVID [17]: cell motility, heat shock, detoxification, sporadic S100.
These proteins were expressed at low or very low levels in the non-tumoral tissues.
4.3.1. Cell Motility Proteins
Motility and migration are distinctive activities of embryonic cells. Adult epithelial cells are
characterized by polarized, adherent and stationary cell sheets, owing to the constraints of cell-cell
and cell-matrix adhesions: these are destroyed during the primary tumor growth, due to the activities
of the matrix metalloproteinases that are over-expressed in the site of primary tumor and, in many
cases, released into the circulation [128].
The loss of polarity and stationarity produces cascading effects, including primarily the
rearrangement of the cytoskeleton and the reactivation of cell motility. Thus, the reorganization
of the actin cytoskeleton plays a central role in the migration of potentially metastatic cells [129].
It is interesting to note that most of the proteins of this group belong to the category of the actin
binding proteins. In Figure 9 the interactome of these proteins is represented, showing that some of
them exhibit a direct link with actin (at the center of the network), and others hold indirect actin links
through the primaries.
This group includes the proteins commented below.
Actin-related protein 2/3 complex subunit 5, ARPC5 (ARPC5). ARPC5 is a component of the ARP2/3
complex, with cofilin, RAB118 and others, which plays a key role in the remodeling of the actin
cytoskeleton, to direct many forms of cellular motility, including vesicle traffic [130]. As shown by the
interactome in Figure 9, ARPC5 interacts directly with ACTB, COTL1, CAP1, COF1, RAB11B. Given its
strategic role in supporting the motile capability of cells, the role of ARPC5 in the tumor progression is
well sustained [131]. This discovery enables the ARP complex to be a viable candidate for a molecular
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targeted therapy against invasion and metastasis [132]. Within our collection of tumor samples, the
ARPC5 expression recurred in 78% of cases at the high expression level, while it proved to be absent,
or at the detection limit, in the normal tissues.
Adenylyl cyclase-associated protein 1, CAP1 (CAP1). The actin-binding CAP1 protein regulates
directly actin filament dynamics, therefore participating in important cellular processes, including
the establishment of cell polarity. Its overexpression in some types of tumors has been related to the
increase of the metastatic potential of cancer cells [133]. In our tumor tissues, we observed the sporadic
presence of two isoforms of CAP1 with a high increase versus the non-tumoral tissues (4.3× and 4.7×.
respectively).
Gelsolin-Like Capping Protein, CAPG (CAPG). CAPG is a calcium-sensitive protein which blocks
reversibly the barbed ends of actin filaments. Its overexpression in cancer has been correlated with
the mechanisms of cell migration and invasiveness and more recently has been associated with breast
cancer progression and bone metastases formation [134]. In our samples, we detected two isoforms,
one of which with a very high increase (19.7×), versus the non-tumoral tissues expressing this protein.
Cofilin1, COF1 (CFL1). In addition to its function in the control of apoptosis, cofilin1 plays a
central role in the dynamics of actin-cytoskeleton remodeling. As shown by the interactome in Figure 9
COF1 interacts directly with ACTB, ARPC5, and CAP1. Indeed, it is involved in the turnover of the
actin branches, so promoting actin filaments treadmilling and participating in the formation of cell
protrusions related to the motile phenotype [135]. This attitude has been proven to be enhanced in
malignant cancer cells [136,137]. As already reported, in our tissue we have found four COF1 isoforms,
on of which ubiquitous and three sporadic. Interestingly, one of the sporadic isoform, when present,
displayed one of the highest average increase (29×) compared to the non-tumoral tissues. The role of
COF1 in the regulation of apoptosis has been already discussed.
Coactosin, COTL1 (COTL1). Coactosin interacts with actin in a calcium-dependent manner,
downstream of the Rac pathway, so promoting the actin polymerization during the formation cell
protrusions [138]. Recently coactosin expression levels have been associated with the metastatic
potential of lung cancer cell lines [139]. In our samples, it showed a very high expression levels (13.6×)
with respect to the non-tumoral tissues. As shown in the interactome, COTL1 interacts directly with
ACTB, ARPC5, and COF1.
Ezrin, EZRI (EZR). EZRI is a member of the ERM family, together with radixin and moesin and
others, is involved in signal transduction, protein trafficking, cell proliferation, migration and in
the establishment and maintenance of the epithelial cell polarity [140]. The EZRI overexpression is
closely related to the breast cancer malignant phenotype, in which the EZRI role seems to be dual: the
participation to the cell protrusion dynamics and to the ERBB2 receptor signaling [141]. It is of interest
to note, that EZRI is among the proteins of the motility that show the highest expression level both in
tumoral and non-tumoral tissues. The interactome in Figure 9, shows that EZRI may interact directly
with ACTB, LEG3, COF1 and CAPG.
Galectin, LEG3 (LGALS3). LEG3 is a galactose-specific lectin associated to the cell membrane
and involved in several processes of the membrane coating and trafficking by interacting with other
surface proteins, including the ANXA2 [142]. Intracellularly LEG3 participates to the cytoskeleton
organization and cell motility by interacting with ACTB, COF1, EZRI, MIF and CAPG (Figure 9).
Extracellularly, it interacts with a variety of cell surface glycoproteins, i.e., growth factor receptors,
integrins and members of the Notch family, and other extracellular matrix molecules [143]. In cancer,
LEG3 seems to participate to the membrane dynamics of cell migration and in the escaping of the
T cells-mediated immune-response [141]. By its overexpression and of its functions in the breast
cancer cells, LEG3 has been recently candidate as a biomarker for the triple-negative breast cancer
progression [144,145]. In our tumor samples LEG3, when present, showed a very high expression level,
while it was absent in the normal tissues.
Macrophage Migration Inhibitory Factor, MIF (MIF). As already reported MIF is an inflammatory
cytokine involved in a great number of cellular pathways, including the control of apoptosis [90].
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During the invasive progression of breast cancer, MIF appears involved in the phenomena of
trans-endothelial cells migration, related to the intra- and extra-vasation processes [91].
As previously indicated, in our tissues we detected two isoforms of MIF, one ubiquitous and the
second sporadic with a high level of expression and absent in the normal tissues. For its proteomic
co-expression with other proteins associated with cell motility, its attribution to this group of proteins
is plausible, but this does not exclude its belonging also the anti-apoptotic group. MIF enters in the
interactome pathway through the interaction with LEG3.
Pyridoxal phosphate phosphatase, PLPP (PDXP). PLPP is a serine phosphatase, having among its
target cofilin. Indeed, the PLPP activity is considered crucial for the regulation of the actin-cytoskeleton
rearrangement mediated by the cofilin [146]. In our maps, it shows a very high expression level (20×)
compared to the non-tumoral tissues.
Receptor of activated protein C kinase, RACK1 (RACK1). RACK1 is involved in the recruitment and
assembly of a variety of signaling molecules, thus playing a role in many cellular processes. Indeed,
it has been reported that RACK1 may play a role in the promotion of breast cancer cell migration,
by binding to and activating RHOA [147]. Interestingly, RACK1 appears absent in the non-tumoral
tissues, while when present in the tumors it is expressed at high levels of intensity. In Figure 9,
its interaction with ACTB, MIF, EZRI and COF1 is shown.
Ras-related protein Rab-11A, RB11B (RAB11B). This protein belongs to the Rho family small
GTPases and, as the other Rho proteins, it is crucial for the machinery of the vesicular-based
intracellular trafficking and for actin reorganization related to the cell motility processes [131]. A recent
study demonstrated a functional relationship between RB11B and the moesin, a member of the
ERM family (Ezrin, Radixin and Moesin), in the mechanisms which coordinate the collective cell
migration [148]. In our maps RB11B, when present, displayed a relatively low increase compared with
the normal tissues.
Stathmin, STMN1 (STMN1). Stathmin is a phosphoprotein mainly involved in the regulation of
the microtubule system in a dual way: by preventing assembly and by promoting disassembly of
microtubules. Some evidence associates the overexpression of the STMN1 to the cancer progression.
Indeed, it has been reported that the MEK-mediated phosphorylation of STMN1 is a key process of
cancer cell migration [149]. Concerning the actin cytoskeleton, stathmin shows to interact with the
COF1 (Figure 9). Interestingly, in our samples stathmin was found highly expressed in some tumors
and absent in the non-tumoral tissues.
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Anterior gradient protein 2 homolog, AGR2 (AGR2). This protein may be secreted from cells, and in
the ECM context, it can potentiate the tumorigenic effects on responding cells [150]. AGR2 expression
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was shown to be significantly increased in HER2 positive breast tumors [151]. High levels of AGR2
were also associated with cell dissemination of pancreatic carcinoma [152] and with poor prognosis of
lung cancer [153]. Worth of note, this protein appears highly represented in the tumor tissues (when
present) and almost absent in the normal ones.
4.3.2. Sporadic Heat Shock Proteins
As already reported, a notable presence of HSP proteins in the tumor tissues was observed. Some
of them were expressed ubiquitously in the tissues and already commented in relation to their key
roles in the control of apoptosis. Other HSPs were found sporadically in our tumor tissues and almost
absent in the normal ones. Many of them have been proposed by several authors as putative biological
markers for tumor progression [80,81,154].
The sporadic heat shock proteins are indicated below.
CH10 (HSPE1) and CH60 (HSPD1). These two chaperonines form a complex mainly involved
in the import of mitochondrial proteins and in the macromolecular assembly. Their involvement
in the tumor progression is still not fully elucidated. The expression level of CH10 in our tumoral
and non-tumoral tissues is under the threshold value of the other Heat Shock Proteins. Concerning
CH60, as already reported, we found four isoforms, three ubiquitous and one sporadic, the latter was
expressed at high level in the tumor tissues, while it was very sporadic in the normal ones and, when
present, it was moderately expressed.
GRP75 (HSPA9). GRP75, also known as “mortalin”, is a mitochondrial chaperone belonging to the
subgroup of the glucose-related proteins. GRP75 is positively involved in the carcinogenetic process,
due to its ability to prevent the transcriptional activation and the pro-apoptotic functions of the p53.
It has been documented that its over-expression correlates with the increase of breast carcinoma cell
malignancy and with poor prognosis for breast cancer patients [155,156]. In our tumor tissues, when
present, it reached high expression values compared to the non-tumoral tissues (5.4×).
Hypoxia up-regulated 1 protein, HYOU1 (HYOU1). HYOU1 belongs to the heat shock protein 70
(HSP70) family. Its primary function is closely related to the cellular responses triggered by oxygen
deprivation; it also plays an important role as a molecular chaperone. HYOU1 results over-expressed
in many tumors, where it appears associated with tumor invasion and with the inhibition of the
drug-induced apoptosis [157]. This protein, when present, displayed a moderate fold increase on the
normal ones.
HS90A (HSP90AA1) and HS90B (HSP90AB1). HSP90s, displaying cytoplasmic and nuclear
localization, play key roles in the protein homeostasis by regulating the folding of many proteins
involved in the control of cell growth, signaling and in the pathogenesis of several human diseases,
especially cancer [158]. It has been demonstrated that the nuclear HSP90 regulates the activity of many
transcription factors and the activity of RNA polymerase II [159]. In our tissue samples, we found a
marked increase in the expression levels of two members of the HSP90 family, namely HS90A and
HS90B, on the non-tumoral tissues.
Parkinson disease protein 7, PARK7/DJ1 (PARK7). As already reported in the previous paragraph,
in our tumor tissues this protein is expressed (at moderate intensity) with four isoforms having similar
MW and different pI. One of them was ubiquitously expressed and already discussed, the others were
found sporadically expressed in the tumors, but also in some of the normal tissues.
Cyclophilin B, PPIB (PPIB). PPIB is a 21-kDa protein having isomerase activity. Its overexpression
in cancer seems to contribute to the neoplastic transformation and progression, through its ability to
regulate the levels of several hormone receptors [160] and to influence the expression of key genes for
the control of cell proliferation and cell motility [161]. In our samples, we found a striking abundance
of this sporadic protein, which is also occasionally present in the non-tumoral tissues at very low levels.
Cyclophilin D, PPIF (PPIF). PPIF is a mitochondrial peptidyl-prolyl isomerase. It acts as a regulator
of the mitochondrial permeability by participating to the control of the pore dynamics. Although its
role in cancer is still unclear, recent studies reported that PPIF up-regulation seems to play a role in
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the tumor progression, through the Paf1/MEK/ERK pathway [162,163]. When present, in our tumor
tissues, this protein was expressed at very high levels.
Prefoldin 2, PFD2 (PFDN2). PFD2 is a subunit of the prefoldin complex, localized in the cytoplasm
and also into the nucleus and crucial for the folding of actin and tubulin [164]. Its overexpression
has been associated with poor prognosis in the bladder carcinoma [165]. Interestingly, this protein is
expressed at high levels in the tumor tissues and absent in the non-tumors.
Cellular retinoic acid-binding protein 2, RABP2 (CRABP2). RABP2 is a retinoic acid binding protein
whose principal role is the delivery of retinoic acid to its nuclear receptor, so modulating the expression
of a large number of genes involved in the control of cell proliferation. The second function of RABP2
is the stabilization of the RNA-binding protein HuR and the strengthening of its interactions with
target mRNAs [166]. RABP2 expression is associated with the growth suppression in a large number of
carcinomas playing a putative anti-oncogenic action [167]. A moderate intensity of it has been detected
in our tissue samples.
Stress-induced phosphoprotein 1, STIP1 (STIP1). STIP1 is a co-chaperone of HSP-70 and -90 and
participates in the JAK2/STAT3 pathway by stabilizing JAK2 protein. The downstream signaling of
JAK2/STAT3 pathway activates several mechanisms responsible for the progression of ovarian and
endometrial carcinomas [168]. When present, this protein is expressed at low levels in the normal
tissues and at moderate levels in the tumoral tissues.
TCP-1-alpha, TCPA (TCP1). TCPA is a molecular chaperone involved in the folding of actin, tubulin
and a large number of proteins (i.e., Cyclin E, Cyclin B and p21ras) with a role in cell proliferation and
neoplastic progression. Its expression is regulated by the signaling downstream tot the PI3K pathway.
According to recent data, the TCPA appears necessary for the in vitro and in vivo survival and growth
of breast cancer cells [169,170]. A moderate increased level of it was detected in the tumors.
4.3.3. Sporadic S100 Proteins
As already mentioned, in our breast cancer tissues we recognized 15 members of S100 family
proteins, seven of which corresponding to six genes, were sporadic as mentioned below. All of them,
when present, showed remarkably increased levels on the normal tissues.
S100P (S100P). S100P is known to function as calcium sensor and to interact with several regulators
of cytoskeleton rearrangement, thus contributing to several cellular physiological processes.
It stimulates cell proliferation and survival via activation of the receptor RAGE [171,172] in an
autocrine manner.
S10A4 (S100A4). The S100A4 protein is known to be secreted by tumor and stromal cells and to
support tumorigenesis by stimulating angiogenesis. Indeed, it has been demonstrated that S100A4
synergizes with vascular endothelial growth factor (VEGF), via the RAGE receptor, in promoting
endothelial cell migration and MMP-9 and MMP-13 gene expression. For this reason, S100A4 protein
is today included in the catalog of the putative therapeutic target [173].
S100A7 (S100A7). Within the sporadic forms of S100 proteins, the S100A7 was one of the most
prominent, also for the high level of relative concentration reached in many cases. Its possible role in
breast cancer has been discussed in a previous work by our group [174] and other authors [175–177].
S10A8 (S100A8), S10A9 (S100A9). These two members of the S100 protein family are known to
play also significant roles in the extracellular fluids during various inflammatory conditions, such as
rheumatoid arthritis, cystic fibrosis and abscesses [178].
S100AD (S100-A13). As previously reported, in our tumor tissues the S100AD displays two
isoforms, the first is ubiquitous and the second, more basic, was sporadic in tumor and absent in the
normal tissues. The functional role of this S100 protein has been already discussed [121,122].
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4.3.4. Detoxification Proteins
The detoxification processes are crucial for the cellular homeostasis in response to the
accumulation of metabolic waste, derived from intracellular pathways or from extracellular responses
to external stimuli, which may interfere with the basic biological functions of the cells. In the neoplastic
cells, this accumulation reaches high levels due to the increased anaerobic metabolism.
The antioxidant enzyme system is very complex, being composed of some vitamins, primary and
secondary antioxidant enzymes and thioredoxin systems [179].
In our tumor tissues, we identified the sporadic expression of 9 detox proteins (encoded by seven
genes), namely: SODC, CATA, PRDX2, PRDX6, GSTP1, ALDR and AK1BA. All of them showed higher
expression levels, with a peak of 27.5 for the PRDX2, as compared with the normal tissues.
It is noteworthy that ALDR, AK1BA and GTSP1 have been associated with cancer progression.
ALDR, AK1BA are enzymes involved in activation and detoxification of carcinogenic polycyclic
aromatic hydrocarbons, a key process for the malignancy in hepatocellular cancer [180]. GSTP1 is
involved in the detoxification functions, however, its silencing appears closely related to the neoplastic
transformation. This evidence suggests a possible role for GSTP1 as a prognostic marker [181].
5. Conclusions
In conclusion, the data obtained on a large scale proteomics platform made it possible to give an
overview on the expression of proteins which appear to be protagonists of a tumor phenotype.
The proteomic analysis of proteins expressed ubiquitously in all patients compared to the sporadic
proteins suggests that the phase of the primary tumor growth must be sustained and supported by
protein clusters capable of ensuring a sustained proliferation not counteracted by normal apoptotic
processes that govern the normal tissue renewal.
Even greater interest was stimulated by the discovery of overexpression to high levels of glycolytic
enzymes, the role of which, the so-called Warburg effect, has already been known since the time of its
discoverer. In fact, two of the key enzymes of the glycolysis, the G3P and the ALDOA, are recognized
as proteins with important oncogenic regulatory functions [182,183]: the first, once nitrosylated enters
into the nucleus and activates gene transcription pathways that support cell proliferation, and the
other that in addition to its role in glycolysis is able to promote epithelial-mesenchymal conversion.
Consequently, primary tumor growth can be ensured by two concordant pathways: the inhibition
of apoptosis and the stimulation of proliferation by the deregulated activity of housekeeping proteins,
including some key enzymes of the glycolysis. We believe that the second phase of the evolution of the
tumor, namely invasion and metastasis, is supported by activities of genes and proteins involved in a
later stage of growth, in particular: proteins involved in cell motility, several S100 proteins and proteins
of the detox machinery, which were sporadic between patients, index probably of a susceptibility to
metastasis in patients who were carriers of these over-expressed proteins.
Future perspective is, therefore, large-scale clinical and molecular correlations with selected
cluster of gene/proteins and follow-up of newly enrolled patients.
Supplementary Materials: Supplementary materials are available online at http://www.mdpi.com/2227-7382/
5/3/15/s1. Figure S1. Panel summarizing the occurrence of the 453 proteins identified in the studied 100 breast
cancer tissues, Table S1: Catalogue of the 453 proteins identified in the studied 100 breast cancer tissues.
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